In the absence of an immediate parenteral antidote, acute organophosphate toxicity in cattle, sheep, horses, and companion dogs progresses from muscarinic and nicotinic collapse to respiratory failure within hours; obidoxime chloride is therefore processed primarily into sterile aqueous injections that can be refrigerated in veterinary emergency kits. The terminal presentation is commonly an aqueous solution of obidoxime chloride at concentrations from 25 mg/mL to 100 mg/mL filled into 10 mL single-dose Type I borosilicate glass ampoules, 20 mL amber Type I vials with grey bromobutyl rubber stoppers, or 50 mL multi-dose vials where a target-species-approved preservative is used; benzyl alcohol is contraindicated in feline formulations. Compliance for this presentation is anchored to Ph. Eur. 2.6.1 Sterility, Ph. Eur. 2.6.14 Bacterial Endotoxins with a calculated limit not exceeding 0.50 EU/mg for a 10 mg/kg bolus dose, Ph. Eur. 2.9.19 Particulate Contamination: Sub-visible Particles, USP <1> Injections, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins Test, USP <788> Particulate Matter in Injections, and EU GMP Annex 1 for sterile manufacture. For a 100 mg/mL batch, 100.0 g of the chloride salt is added per 1000 mL of Water for Injection with an assay-based overage of 1.0% to 2.0% w/w to offset fill-volume loss and moisture uptake; the solution is cooled to 15°C to 20°C before pH adjustment to 2.8 to 3.5 with 0.1 M hydrochloric acid because higher pH values accelerate reversible oxime hydrolysis and reduce the capacity to reactivate phosphorylated acetylcholinesterase. The manufacturing process in a 500 L 316L stainless steel jacketed vessel with a bottom-mounted 0.5 kW agitator operating at 200 rpm to 300 rpm proceeds under a 0.2 bar nitrogen overlay to exclude atmospheric carbon dioxide; after dissolution, the batch is passed through a 0.45 µm polypropylene prefilter and a 0.22 µm double-layer polyethersulfone sterilizing filter before aseptic filling in an ISO 5 laminar airflow line. Process validation is expected to demonstrate a maximum hold time of 8 h between filtration and filling at 20°C with a pre-filtration bioburden not exceeding 10 CFU/100 mL; if terminal steam sterilization is used, a 121°C for 15 min cycle is permissible only after differential scanning calorimetry and solution stability data show not more than 5% assay loss at the target pH. On high-speed vial lines operating above 20,000 vials/h, foaming generated by top-entry agitators can elevate particulate counts above the Ph. Eur. 2.9.19 limit; the defect is controlled by bottom-fill nozzles, reduced agitator speed, and a vertical drop height not exceeding 50 cm. Table 1 lists formulation gradients for injection strengths encountered in batch production.

Table 1. Comparative formulation gradients for obidoxime chloride injection

When Is Lyophilization Preferable to Terminal Sterile Filtration for Oxime Injectables?

Thermolabile oxime salts and pH-adjusted aqueous fills are not always stable over multi-year distribution in tropical veterinary cold chains; a lyophilized presentation is selected when reconstituted intravenous or intramuscular use must remain viable in warehouses that exceed 30°C excursions. The terminal product is a sterile cake in 20 mL Type I borosilicate glass vials containing 250 mg of obidoxime chloride per vial, with a bulk solution at 50 mg/mL obidoxime chloride, 2.5% to 5.0% w/v mannitol or glycine as bulking excipient, and 10 mM citrate buffer at pH 3.0 to 3.5. Compliance includes Ph. Eur. 2.6.1, Ph. Eur. 2.6.14, Ph. Eur. 2.9.19, Ph. Eur. 2.5.12 moisture determination with cake moisture not exceeding 2.0% w/w, USP <71>, USP <921>, and vial closure integrity testing under USP <1207> using deterministic helium leak detection rather than dye ingress alone. The bulk solution is compounded as a 50 mg/mL solution by adding 0.50 kg of API to 10 L of Water for Injection, adjusting pH with citric acid, filtering through 0.22 µm polyethersulfone membrane, and filling 5.0 mL per 20 mL vial before loading onto a freeze-dryer with 10 m² shelf area and ±0.5°C shelf uniformity. Freezing is performed at -45°C for 3 h; primary drying is set at -20°C shelf temperature with chamber pressure 80 µbar to 150 µbar for 48 h, and secondary drying is performed at 25°C for 6 h until moisture is below 2.0%. The selected primary-drying shelf temperature must remain 2°C to 3°C below the freeze-drying microscopy collapse temperature of the excipient system; because glycine changes resistance to vapor flow and collapse behavior, lyophilization cycle design cannot be copied from mannitol-containing batches without new thermal characterization. On automated loading lines running 50 vials/min, breakage occurs when tray slot guides are not matched to 20R glass tubing dimensions; the defect is eliminated by using chrome-plated guide rails and by verifying glass geometry before campaign start. Lyophilization adds 24 h to 48 h of freeze-dryer occupancy and is not required for liquid presentations that can be terminally sterilized; the route is justified when 3-month accelerated testing at 40°C/75% RH demonstrates unacceptable aqueous hydrolysis in the pH 2.8 to 3.5 liquid state.

Because field veterinarians may need a solid oral maintenance dose after initial parenteral loading in non-food-producing animals, tablet compression of obidoxime chloride is carried out under low-humidity conditions and is subject to explicit bioavailability limitations: the quaternary ammonium structure reduces passive intestinal permeability, so oral tablets are not indicated for acute severe poisoning and must be dosed only under veterinary direction. The terminal product is a film-coated tablet in 100 mg or 250 mg strengths, packaged in PVC/PVDC-aluminium blisters or HDPE bottles containing a desiccant. Compliance requires Ph. Eur. 2.9.5 uniformity of mass, USP <905> Uniformity of Dosage Units, Ph. Eur. 2.9.7 friability, USP <1216> Tablet Friability, Ph. Eur. 2.9.3 dissolution in 0.1 M hydrochloric acid, USP <711> Dissolution, and disintegration under Ph. Eur. 2.9.1/USP <701>. A representative core formulation contains 35.0% w/w API, 48.0% w/w microcrystalline cellulose, 5.0% w/w crospovidone, 2.0% w/w povidone K30 as binder, 0.5% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate, with granulating liquid being purified water or 20% ethanol-water at 15% to 20% w/w of dry mass. The API is hygroscopic; if Karl Fischer moisture exceeds 1.0% w/w, the active ingredient is pre-dried at 40°C for 4 h before weighing. Wet granulation in a 200 L vertical high-shear mixer with an impeller speed of 300 rpm and chopper speed of 1500 rpm proceeds for 2 min; the wet mass is dried in a fluid-bed drier with inlet air at 55°C to a loss-on-drying specification of 1.5% to 2.5% w/w, then milled through a 0.8 mm screen. Compression on a rotary tablet press using 12.0 mm round punches achieves tablet hardness 90 N to 120 N, with ejection force below 600 N; batch-to-batch variation in spray-dried API particle size distribution can shift ejection force by ±15% if the fines fraction below 50 µm is not controlled. The film coating is a moisture-protective HPMC-based system applied to 2.0% to 3.0% w/w weight gain. Alkaline fillers such as sodium bicarbonate or magnesium oxide must be avoided because microenvironmental pH above 4.5 accelerates oxime degradation; tablets are intended only for non-food-producing species unless an MRL and withdrawal period are established.

Water-Soluble Powder and Premix Production for Managed Animal Populations

For managed animal populations where parenteral logistics are temporarily unavailable, water-soluble powder and premix presentations are prepared as oral emergency alternatives; published pharmacokinetic data for this specific configuration is limited, so the powder route is not interchangeable with parenteral administration and is generally reserved for hospital or field-stock controlled use. The terminal product is a water-soluble powder in 10 g or 100 g foil-lined sachets or 1 kg HDPE jars, yielding an oral solution of 1 mg/mL to 5 mg/mL when reconstituted in potable water by the user. Compliance is anchored to USP <786> particle size sieve analysis, USP <616> bulk and tapped density, Ph. Eur. 2.9.34 bulk and tapped density, and non-sterile oral product microbial enumeration under Ph. Eur. 5.1.4 or USP <61> and <62>. A representative addition ratio is 15.0% w/w API, 79.0% w/w dextrose monohydrate or spray-dried lactose as water-soluble carrier, 3.0% w/w citric acid, 1.0% w/w colloidal silicon dioxide, and 2.0% w/w pregelatinized starch as dispersant; the carrier is selected to ensure complete dissolution in 2 min at 25°C without residual solids. Manufacturing uses a 200 L stainless-steel ribbon mixer at 15 rpm to 20 rpm with geometric dilution of the API in three equal carrier portions; the blend is passed through a 500 µm mesh and filled at 20°C to 25°C and not more than 35% RH because moisture uptake above 2.0% w/w causes bridging in the filler hopper and failure of the target fill weight. Feed premix applications are not supported by sufficient target-species data for obidoxime chloride and must be justified by a veterinary risk assessment; a drinking-water premix may be manufactured only if the final reconstituted pH is maintained at 3.0 to 4.0 to reduce oxime degradation. On rotary sachet fillers running 60 units/min, hygroscopic caking at the filling shoe is the main defect mode; it is controlled by installing a continuous nitrogen purge and by using pre-dried carrier with moisture below 0.5% w/w.

Capsule-based dosage forms of obidoxime chloride are produced in small-scale non-sterile oral solid lines where dose-unit flexibility is required for non-food-producing companion animals; the oral route is subject to the same low systemic bioavailability constraints as tablets and is not a first-line treatment in acute severe organophosphate poisoning. The terminal product is a hard gelatin or hypromellose capsule, size 3 or 4, containing 50 mg or 100 mg of API, packaged in PVC/PVdC blisters or HDPE bottles with desiccant. Standards include USP <905> Uniformity of Dosage Units, Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.1/USP <701> disintegration, USP <711> dissolution, and envelope moisture testing under Ph. Eur. 2.5.12/USP <921>. A representative fill formulation contains 30.0% w/w API, 54.0% w/w lactose monohydrate, 6.0% w/w sodium starch glycolate, 0.5% w/w colloidal silicon dioxide, and 1.0% w/w magnesium stearate; the blend is prepared in a 100 L tumble blender at 25 rpm for 15 min, and blending is stopped immediately after addition of magnesium stearate to avoid over-lubrication. The API and lactose are pre-dried at 40°C for 4 h if moisture exceeds 1.0% w/w; the capsule filling environment is maintained at 20°C to 25°C and 30% to 35% RH because hard gelatin becomes brittle below 30% RH and soft above 50% RH. A dosator-type capsule filling machine operating at 30,000 capsules/h with 150 mg target fill weight is used; fill weight variation across 10% of capsules is controlled by dose-plate spring tension and by maintaining particle size distribution of the API below 250 µm. The formulation must not include alkaline disintegrants that raise the local pH above 4.5; if sodium starch glycolate is used, dissolution is confirmed in 0.1 M hydrochloric acid and the final pH remains below 4.5.

Where Oral Solution and Granule Forms Are Used in Veterinary Hospitals

In veterinary hospital pharmacies, ready-to-use oral solution and reconstitutable granules are manufactured for nasogastric or dose-syringe administration in equine and small-animal patients when parenteral access is not possible; these forms are not substitutes for intravenous antidote therapy and oral absorption is limited by the same quaternary ammonium charge that restricts intestinal permeability. The oral solution terminal product is a 1 mg/mL or 5 mg/mL solution in 100 mL amber PET bottles with child-resistant caps; the granule terminal product is a 1 g or 5 g unit-dose sachet for reconstitution to 5 mL or 25 mL of potable water. Solution compliance includes pH measurement, Ph. Eur. 5.1.4 or USP <61>/<62> microbial examination of non-sterile products, and preservative efficacy testing under Ph. Eur. 5.1.3/USP <51> only for multi-dose containers; granules are tested under Ph. Eur. 2.9.5 uniformity of mass and USP <905>. For the solution, 1.0 g of API is dissolved per 100 mL purified water to produce 1 mg/mL, or 5.0 g per 100 mL for 5 mg/mL; citric acid is added at 0.05% w/v to bring pH to 3.2 to 3.8, and a preservative system such as 0.08% w/v methyl parahydroxybenzoate plus 0.10% w/v potassium sorbate is used only when multi-dose use is expected. The liquid is mixed in a stainless-steel tank at 100 rpm for 15 min, passed through a 5 µm polypropylene filter, and filled at 20°C to 25°C; light-protective amber bottles are required because oxime salts undergo photodegradation under prolonged UV exposure. Granules are prepared by fluid-bed granulation with a binder solution of 2.0% w/w povidone K30 in water; the dry mix contains 40.0% w/w API, 55.0% w/w mannitol, 1.0% w/w citric acid, and 1.0% w/w colloidal silicon dioxide. Inlet air at 60°C maintains product temperature at 35°C until granule moisture is below 2.0% w/w; the dried granules are sieved through 710 µm and filled into sachets at 35% RH or less. Equipment-related defect modes include preservative sorption onto PET bottle walls over 3 months in high-surface-area containers; this is controlled by using fluoropolymer-lined caps and by accelerated stability testing at 40°C/75% RH to justify the assigned shelf life. Published data for this specific configuration is limited for some target species, so formulation batches must be supported by veterinary prescribing information that defines the route, dose, and species.